ONCAlert | 2018 ASCO Annual Meeting
Hepatocellular Carcinoma Case Studies

Case Studies: Considerations Following Locoregional Therapy in HCC

In this case-based interview, Ghassan Abou-Alfa, MD, describes the case of a 64-year old female with a history of obesity, fatigue, unexplained weight loss, and fatty-liver disease.

Considerations Following Locoregional Therapy in HCC

May 2015

  • 64-year old obese female presented with fatigue and unexplained weight loss
  • History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
  • Lab results: AFP= 1,500 IU/ml
  • ECOG=1; Child-Pugh A
  • CT revealed 1 large liver mass, right side of liver close to a major blood vessel
  • No extrahepatic disease
  • Liver-directed therapy with DEB-TACE was performed
  • Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
  • Patient had a complete response
  • AFP= 200 IU/ml at follow up

February 2017

  • Follow-up imaging showed progression and evidence of bone metastases
  • Therapy was initiated with sorafenib at 400 mg BID
  • Follow-up testing showed liver decompensation
Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.